CD44 expression predicts disease outcome in localized large B cell lymphoma

Diffuse large B cell non-Hodgkin’s lymphomas (DLCL) form a heterogeneous group of tumors with diverse morphology, clinical features, treatment response and prognosis. The biological variables underlying this heterogeneity are unknown. In the present study, we explored the value of the lymphocyte homing receptor CD44, a putative determinant of lymphoma dissemination, in predicting prognosis in DLCL. Expression of the standard form of CD44 (CD44s) and of CD44 isoforms containing exon v6 (CD44v6) on tumor cells was assessed by immunohistochemistry in a cohort of 276 DLCL patients from a population based lymphoma registry. We observed that CD44s as well as CD44v6 expression correlated with tumor dissemination in patients with primary nodal DLCL. Importantly, in patients with localized nodal disease, CD44s was a strong prognosticator predicting tumor related death independent of the other parameters of the International Prognostic Index (IPI). Incorporation of CD44s in the IPI parameter ‘stage’, increased the prognostic value of this parameter in nodal DLCL. Our data identify CD44 as a biological prognosticator, which can be used to ‘fine-tune’ the IPI for nodal DLCL.

[1]  B. Imhof,et al.  Expression of integrins and CD44 isoforms in non‐Hodgkin's lymphomas: CD44 variant isoforms are preferentially expressed in high‐grade malignant lymphomas , 1994, The Journal of pathology.

[2]  P. Kincade,et al.  CD44 and its interaction with extracellular matrix. , 1993, Advances in immunology.

[3]  D. Parker.  Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. , 1995, Lancet.

[4]  K. Miyake,et al.  Monoclonal antibodies to Pgp-1/CD44 block lympho-hemopoiesis in long- term bone marrow cultures , 1990, The Journal of experimental medicine.

[5]  J. R. de los Toyos,et al.  Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells , 1987, The Journal of cell biology.

[6]  D. Neuberg,et al.  A directly spliced exon 10-containing CD44 variant promotes the metastasis and homotypic aggregation of aggressive non-Hodgkin's lymphoma. , 1998, Blood.

[7]  C. Meijer,et al.  Expression of lymphocyte homing receptor as a mechanism of dissemination in non-Hodgkin's lymphoma. , 1989, Blood.

[8]  E. Puré,et al.  CD44 is necessary for optimal contact allergic responses but is not required for normal leukocyte extravasation , 1993, The Journal of experimental medicine.

[9]  P. Herrlich,et al.  Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44 , 1993, The Journal of experimental medicine.

[10]  B. Caillou,et al.  CD44 contributes to T cell activation. , 1989, Journal of immunology.

[11]  I. Stamenkovic,et al.  Distinct effects of two CD44 isoforms on tumor growth in vivo , 1991, The Journal of experimental medicine.

[12]  E. Manten-Horst,et al.  Adhesion molecules in the dissemination of non-Hodgkin's lymphomas. , 1997, Acta haematologica.

[13]  R. Clark,et al.  CD44 and hyaluronan-dependent rolling interactions of lymphocytes on tonsillar stroma , 1996, The Journal of cell biology.

[14]  M. Ladanyi,et al.  Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. , 1994, The New England journal of medicine.

[15]  F M van den Berg,et al.  Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. , 1993, Cancer research.

[16]  K. Offit,et al.  BCL-6 in diffuse large-cell lymphomas. , 1996, Important advances in oncology.

[17]  S. Jalkanen,et al.  Prognostic value of lymphocyte homing receptor and S phase fraction in non-Hodgkin's lymphoma. , 1990, Blood.

[18]  R. Fisher,et al.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.

[19]  Klaus Rajewsky,et al.  Somatic hypermutation in normal and transformed human B cells , 1998, Immunological reviews.

[20]  H. Degrendele,et al.  Requirement for CD44 in activated T cell extravasation into an inflammatory site. , 1997, Science.

[21]  Brian Seed,et al.  A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family , 1989, Cell.

[22]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[23]  L. Picker,et al.  CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte-endothelial cell primary adhesion pathway , 1996, The Journal of experimental medicine.

[24]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[25]  K. Heider,et al.  Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys. , 1995, European journal of cancer.

[26]  G. Salles,et al.  Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. , 1993, Blood.

[27]  S. Jalkanen,et al.  A lymphoid cell surface glycoprotein involved in endothelial cell recognition and lymphocyte homing in man , 1986, European journal of immunology.

[28]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[29]  R. Pieters,et al.  Expression of a human homing receptor (CD44) in lymphoid malignancies and related stages of lymphoid development. , 1990, Leukemia.

[30]  E. Jaffe,et al.  Molecular genetics of gastrointestinal non-Hodgkin's lymphomas: unusual prevalence and pattern of c-myc rearrangements in aggressive lymphomas. , 1990, Blood.

[31]  I. Stamenkovic,et al.  Induction of Apoptosis of Metastatic Mammary Carcinoma Cells In Vivo by Disruption of Tumor Cell Surface CD44 Function , 1997, The Journal of experimental medicine.

[32]  E. Noordijk,et al.  Treatment, patterns of failure, and survival of patients with Stage I nodal and extranodal non‐Hodgkin's lymphomas, according to data in the population‐based registry of the comprehensive cancer centre west , 1998, Cancer.

[33]  W. Eisterer,et al.  CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. , 1995, Blood.

[34]  K. Musshoff.  Klinische Stadieneinteilung der Nicht-Hodgkin lymphome , 1977 .

[35]  P. Herrlich,et al.  CD44 variant exon epitopes in primary breast cancer and length of survival , 1995, The Lancet.

[36]  E. Noordijk,et al.  Gastric lymphomas compared with lymph node lymphomas in a population‐based registry differ in stage distribution and dissemination patterns but not in patient survival , 1997, Cancer.

[37]  J. Bell,et al.  Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon , 1995, The Journal of cell biology.

[38]  J Hermans,et al.  International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. , 1995, Blood.

[39]  Martin Hofmann,et al.  A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells , 1991, Cell.

[40]  J. Bell,et al.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J Hermans,et al.  Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. , 1998, Blood.

[42]  S. Jalkanen,et al.  Lymphocyte homing and clinical behavior of non-Hodgkin's lymphoma. , 1991, The Journal of clinical investigation.

[43]  C. Figdor,et al.  Triggering of the CD44 antigen on T lymphocytes promotes T cell adhesion through the LFA-1 pathway. , 1990, Journal of immunology.

[44]  K. Lennert,et al.  Updated Kiel classification for lymphomas , 1989, The Journal of pathology.

[45]  C. Meijer,et al.  Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). , 1990, Leukemia.

[46]  M. Shipp.  Can we improve upon the International Index? , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  D. Jong,et al.  Clinical Relevance of BCL 2 , BCL 6 , and MYC Rearrangements in Diffuse Large B-Cell Lymphoma , 1998 .